PROS1 and prostate cancer: One such study called the European Randomised Study of Screening for Prostate Cancer (ERSPC) randomized more than 180,000 men from Europe to analyse the longitudinal relationship between PSA values and biopsy (biopsy was carried out if blood PSA level was 3.0 ng/mL or higher) at regular intervals (every 4 years).